Immunotherapy and Vaccine-Based Approaches for Atherosclerosis Prevention: A Systematic Review Study Publisher Pubmed



M Shekarchizadehesfahani MANSOUREH ; M Siavash Dastjerdi MANSOUR ; Rs Sajad Raheleh SADAT ; A Ramezani Ahmadi AMIRHOSSEIN ; M Karimifar MOZHGAN ; Me Akbari Mojtaba E ; M Shekarchizadeh MASOOD
Source: BMC Cardiovascular Disorders Published:2025

Abstract

Introduction: Cardiovascular disease is a major global health issue, and atherosclerosis is a leading cause of cardiovascular conditions. Traditional approaches for managing atherosclerosis have limitations, creating a need for alternative preventive strategies such as vaccines. Methods: The authors conducted a systematic review following Cochrane Handbook and PRISMA guidelines. They searched multiple databases for studies on preventive vaccines against atherosclerosis, including clinical trials and experimental models. The search period was from 1950 to August 2024. Results: After screening and evaluation, 47 studies were included in the systematic review. The studies investigated various vaccine candidates and immunization strategies. Vaccination goals involve targeting proteins that are found in higher quantities in individuals with atherosclerosis, such as oxidized low-density lipoprotein (LDL), apolipoprotein B-100, proprotein convertase subtilisin/kexin type-9 serine protease (PCSK9), cholesteryl ester transfer protein (CETP), and heat shock proteins HSP60 and HSP65. The review highlights the potential of vaccines in preventing atherosclerosis by targeting specific antigens, modulating lipoprotein metabolism, and enhancing immune responses. Promising approaches included PCSK9 inhibitors, virus-like particle (VLP)-based vaccines, and gene-editing techniques. Monoclonal antibodies like alirocumab, designed to inhibit PCSK9, were also effective in reducing LDL cholesterol levels. Conclusion: This systematic review provides insights into the progress, challenges, and future directions of preventive vaccine research against atherosclerosis. The findings support the development of effective vaccines to complement existing preventive strategies and reduce the global burden of cardiovascular diseases. Clinical trial number: It is not applicable. © 2025 Elsevier B.V., All rights reserved.